An­oth­er one of Bris­tol-My­er­s' PD-1/CT­LA-4 com­bo stud­ies bites the dust

Bris­tol-My­ers Squibb can move an­oth­er Op­di­vo/Yer­voy com­bo study to the loss col­umn.

In its quar­ter­ly re­view out Thurs­day morn­ing, the trou­bled gi­ant not­ed briefly that their Phase II study com­par­ing the PD-1/CT­LA-4 com­bo against Op­di­vo alone failed in pa­tients with re­cur­rent or metasta­t­ic squa­mous cell car­ci­no­ma of the head and neck.

All we know right now is that the top-line da­ta demon­strate the com­bo failed its pri­ma­ry end­points: the over­all re­sponse rate as well as du­ra­tion of re­sponse, ac­cord­ing to clin­i­cal­tri­als.gov.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER